NEW YORK, Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form-2/?id=127834&from=4CLASS PERIOD: Februar ...

Core Viewpoint - A securities class action lawsuit has been filed against Cassava Sciences, Inc. for allegedly making false and misleading statements regarding its drug simufilam and its effectiveness in treating Alzheimer's Disease during the specified Class Period from February 7, 2024, to November 24, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased or acquired Cassava securities during the Class Period [1]. - The lead plaintiff deadline for the lawsuit is February 10, 2025 [1]. - The complaint alleges that Cassava's drug simufilam was not capable of abating the progression of Alzheimer's Disease, which misrepresented the company's business and prospects [2]. Group 2: Legal Process - Investors may seek to be appointed as a lead plaintiff representative by the deadline or may choose to remain absent [3]. - The lead plaintiff will act on behalf of all class members and select counsel to represent the class [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].

Core Viewpoint - A class action securities lawsuit has been filed against Cassava Sciences, Inc. due to alleged securities fraud related to its drug candidate simufilam, which failed to meet clinical trial endpoints, leading to significant stock price decline [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud between February 7, 2024, and November 24, 2024 [1]. - Defendants allegedly provided misleading information regarding simufilam's efficacy in treating Alzheimer's Disease, expressing confidence that was not substantiated by trial results [2]. - Following the release of disappointing Phase 3 study results on November 25, 2024, Cassava's stock plummeted from $26.48 to $4.30, a drop of approximately 83.76% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until February 10, 2025, to request appointment as lead plaintiff, although participation in recovery does not require this role [3]. - Class members may be eligible for compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Cassava Sciences, Inc. regarding a class action lawsuit related to the company's drug candidate simufilam, which failed to meet clinical trial endpoints, leading to a significant stock price decline [1][2]. Group 1: Allegations and Impact - Shareholders who purchased shares of Cassava Sciences (SAVA) between February 7, 2024, and November 24, 2024, are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [1]. - The complaint alleges that the defendants provided misleading information about simufilam's efficacy in treating Alzheimer's Disease, expressing confidence that was not substantiated by trial results [1]. - Following the release of disappointing Phase 3 study results on November 25, 2024, Cassava's stock plummeted from $26.48 to $4.30 per share, a decline of approximately 83.76% in one day [1]. Group 2: Next Steps for Shareholders - The deadline for shareholders to register for the class action is February 10, 2025, and they will be enrolled in a portfolio monitoring system for updates on the case [2]. - Participation in the case does not incur any costs or obligations for shareholders [2]. Group 3: Firm's Commitment - The Gross Law Firm is recognized for its commitment to protecting investors' rights against deceit and fraud, aiming to hold companies accountable for misleading practices that inflate stock prices [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Cassava Sciences, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought Cassava securities between February 7, 2024, and November 24, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 10, 2025 [3]. - The lawsuit alleges that Cassava Sciences misrepresented the reliability of information regarding its drug prospects and downplayed risks associated with its leading drug candidate, simufilam [5]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4]. Group 3: Case Background - The lawsuit claims that Cassava Sciences created a false impression of confidence in simufilam's potential to treat Alzheimer's Disease, despite lacking evidence to support such claims [5]. - When the true nature of the drug's efficacy became known, investors reportedly suffered damages as a result of the misleading information [5].

Core Viewpoint - A class action lawsuit has been filed against Cassava Sciences, Inc. regarding allegations of securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves Cassava and certain officers and/or directors, with a deadline of February 10, 2025, for investors to request appointment as Lead Plaintiff [2]. - Investors who purchased or acquired Cassava securities during the Class Period are encouraged to contact Pomerantz LLP for participation [1][2]. Group 2: Company Performance - On November 25, 2024, Cassava announced that its drug simufilam failed to meet all pre-specified endpoints in a Phase 3 study for treating mild-to-moderate Alzheimer's disease [3]. - Following the announcement, Cassava's stock price plummeted by $22.19 per share, a decrease of 83.78%, closing at $4.30 per share [4]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering billions in damages for class members [5].

RADNOR, Pa., Jan. 31, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the "Class Period"). The lead plaintiff deadline is February 10, 202 ...

NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ps ...

Lawsuit Overview - A securities class action lawsuit has been filed against Cassava Sciences Inc (NASDAQ: SAVA) in the United States District Court for the Western District of Texas [1] - The lawsuit is on behalf of investors who purchased or acquired Cassava securities between February 7, 2024, and November 24, 2024 [1] - The lead plaintiff deadline is February 10, 2025 [1] Allegations Against Cassava Sciences - Defendants allegedly made materially false and/or misleading statements during the Class Period [2] - Defendants failed to disclose material adverse facts about the company's business, operations, and prospects [2] - Specifically, Cassava's drug simufilam was not capable of abating the progression of Alzheimer's Disease, even in mild to moderate cases [2] - As a result, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis [2] Lead Plaintiff Process - Cassava investors may seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel by February 10, 2025 [3] - The lead plaintiff is usually the investor or small group of investors with the largest financial interest who are also adequate and typical of the proposed class of investors [3] - The lead plaintiff selects counsel to represent the lead plaintiff and the class [3] About the Law Firm - Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world [4] - The firm has recovered billions of dollars for victims of fraud and other corporate misconduct [4] - The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP [4]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cassava To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Cassava between February 7, 2024 and November 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Jan. 23, 2025 /PRNewswire/ -- Faruqi & Far ...